C-reactive protein (CRP) is an acute phase reactant and a marker of inflammation in the human body. Some studies have reported high sensitive CRP (hsCRP) is a marker of cardiovascular diseases not only in western countries but also in Japan. Danesh et al reviewed the relationship between CRP and coronary heart disease (CHD). The odds ratio of the top third to the bottom third was about 1.5 on a meta-analysis.

Because some cross-sectional studies reported that CRP correlate with obesity, high triglycerides, low high-density lipoprotein (HDL) cholesterol and abnormal glucose metabolism, the relationship between CRP and metabolic syndrome has received attention in recent years. In some other studies, CRP was a predictor of future metabolic syndrome. Ridker et al indicated that the interrelationship between hsCRP and metabolic syndrome strongly predicts CHD and CVD death. A recent statement from the Centers for Disease Control and Prevention and the American Heart Association concluded that it is reasonable to measure CRP as an adjunct to the measurement of established risk factors in order to assess the risk of coronary heart disease. It is necessary to use stored samples in nested-case control
studies or cohort studies, when we examine new risk factors. Many cohort studies\(^1\,^2\,^3\,^4\) and nested case-control studies\(^5\,^6\,^7\) have examined the relationship between CRP and CVD using frozen samples stored for many years.

Variability in the measurement of CRP under various situations, including freeze/thaw experiments did not affect the levels of CRP over a short period of time.\(^2\,\,^8\) However, the long-term stability of CRP values in frozen samples has not been examined previously. In the present study, we measured CRP values before and after long-term storage, and examined the long-term variability of CRP values in frozen samples.

HsCRP was measured before and after long-term storage of samples obtained from 99 men and women among the JMS Cohort Study subjects. A detailed description of the JMS Cohort Study was reported previously.\(^2\,\,^4\) The subjects were population-based and were followed for incidences of stroke and myocardial infarction. CRP was measured with non-thawed serum samples at the baseline in 6,759 participants (2,573 men and 4,186 women). After an average storage period of 13.8 years, we selected 99 samples (45 men and 54 women) by the stratified random sampling method using baseline CRP values. Distribution of CRP values is highly skewed, and we intended to select samples showing various levels of CRP at the baseline. Blood samples were obtained in the morning after an overnight fast, and drawn from the antecubital vein of seated subjects with minimal tourniquet use. Tubes were centrifuged at 3,000 g for 15 minutes at room temperature within two hours after sampling. After separation, the serum samples were stored at \(-80^\circ C\) in refrigerated containers with dry ice for a maximum of 6 hours, and then frozen as rapidly as possible at \(-80^\circ C\) for storage until laboratory tests were performed.

At the baseline, CRP values were measured from serum samples using highly sensitive nephelometry, a latex particle-enhanced immunoassay (NA Latex CRP Kit, Dade Behring, Tokyo, Japan). The value in the calibrator was assigned using cer-.

We showed the intra-individual variability of CRP values obtained before and after 13.8 years of frozen storage. We found a close relationship between the two measurements, but CRP values examined after long-term storage were significantly higher than those at the baseline.

Our colleagues reported previously that CRP values were lower in Japanese than in western subjects, were less than the lowest detection value (0.03 mg/L) in more than 10% of the subjects in the general population,\(^2\,\,^8\) and that intra-individual correlation coefficient over 5 years was 0.43.\(^7\) In the present study, we selected 99 subjects among those who underwent CRP examination at the baseline using the stratified sampling method. Distribution of CRP was highly skewed, and the values of CRP would be mainly in the lower level when random sampling was performed. We tried to examine reproducibility after long-term storage using a wide spectrum of the CRP values; from less than the minimum to more than 30 mg/L.

It has been reported that CRP value remains stable in a frozen sample.\(^2\,\,^8\) Macy et al\(^2\) reported several types of intra-individual variability using samples collected at a single time point. They compared sample types; serum, SCAT-1 plasma, SCAT-2 plasma, EDTA plasma, and citrate plasma samples in six individuals, CRP values were lower in sodium citrate tubes than in other types of
We stored samples at 4°C within 2 hours after processing specimens, after that hsCRP was measured using serum samples within few days. Otherwise, only one thaw-freeze cycle was performed before long-term storage of plasma samples. It was considered that neither our measurement procedure nor storage critically affected the levels of CRP.

We first measured CRP values using serum sample at the baseline, and second using thawed plasma sample after long-term storage. According to the study by Macy et al., the fact that the CRP values of the second measurement were higher than those of the first was not due to the different types of sample tubes. They also compared values in a freeze/thaw experiment and thawed samples once, twice, three, and four times using the same 5 types of tubes. There were no significant differences in the mean value of CRP and CRP remained stable throughout multiple freeze/thaw cycles. Aziz et al. confirmed that stability of CRP levels did not differ between serum and plasma samples, or after 7 freeze-thaw cycles. They also found that there were no significant differences in CRP levels with up to a 6 hour delay in specimen processing. Nisson et al. reported in 34 patients admitted to a coronary care unit using 10 year frozen samples that hsCRP showed a predictable slope in the regression between serum and citrate plasma (\((\text{hsCRP})_{\text{citrate}} = 0.902 \times (\text{hsCRP})_{\text{serum}} – 0.1695)).

Table 1. General characteristics of the subjects with two measurements of C-reactive protein

|                          | n  | Mean    | SD    |
|--------------------------|----|---------|-------|
| Age (years)              | 99 | 53.6    | 11.9  |
| Body mass index (kg/m²)  | 81 | 23.2    | 3.2   |
| Systolic blood pressure (mmHg) | 81 | 126.0  | 19.5  |
| Diastolic blood pressure (mmHg) | 81 | 74.9   | 11.4  |
| Total cholesterol (mg/dL) | 99 | 198.1   | 34.8  |
| Triglycerides (mg/dL)     | 99 | 110.0 (58.7-206.1) |
| HDL-cholesterol (mg/dL)   | 99 | 46.9    | 12.2  |

Sex (Men/Women) 45/54

Smoking

- Current: 16 (20)
- Ex-smoker: 15 (19)
- Non-Smoker: 50 (62)

Alcohol drinking

- Current: 41 (51)
- Ex-drinker: 3 (4)
- Drinker: 37 (46)

*: Geometric mean (standard deviation)
**: Number (percentage)

Table 2. The values of C-reactive protein before and after 13.8 years interval.

|                  | n  | 1    | 25   | 50    | 75    | 99    |
|------------------|----|------|------|-------|-------|-------|
| CRP, first (mg/L)| 99 | 0.015| 0.130| 0.230 | 0.470 | 40    |
| CRP, second (mg/L)| 99 | 0.025| 0.307| 0.568 | 0.960 | 31.3  |

|                  | Geometric mean | Standard deviation |
|------------------|----------------|--------------------|
| CRP, first (mg/L)| 0.251          | (0.04-1.40)        |
| CRP, second (mg/L)| 0.587    | (0.17-1.99)        |

CRP, first: measured at the baseline
CRP, second: measured after defrosted with 13.8 years interval
*: Geometric mean (standard deviation)
**: p<0.0001 by paired t-test

We stored samples at 4°C within 2 hours after processing specimens, after that hsCRP was measured using serum samples within few days. Otherwise, only one thaw-freeze cycle was performed before long-term storage of plasma samples. It was considered that neither our measurement procedure nor storage critically affected the levels of CRP.

We first measured CRP values using serum sample at the baseline, and second using thawed plasma sample after long-term storage. According to the study by Macy et al., the fact that the CRP values of the second measurement were higher than those of the first was not due to the different types of sample tubes. The variability of differences between the two measurements could not be
Figure 1. Plots of raw C-reactive protein measurements before and after storage for 13.8 years. Samples were measured at the baseline (CRP, first), and after thawing following long-term frozen storage (CRP, second).

Figure 2. Plots of logarithm of C-reactive protein measurements before and after storage for 13.8 years. Samples were measured at the baseline (CRP, first), and after thawing following long-term frozen storage (CRP, second).

explained by regression to the mean phenomenon because we selected samples using stratified methods, but only the lower values of CRP at the first measurement showed an increase, while higher CRP levels did not decline. We speculated that differences between the two measurements were caused by evaporation during long-term frozen storage, and especially affected low CRP values. Another possibility is that progressive changes in the precipitability of some proteins might occur. A linear relationship was seen in both Figures 1 and 2, and the values converged toward a high level of CRP.

To our knowledge, this is the first study to examine the stability between before and after long-term interval of frozen storage. Some limitations exist in the present study. First, we selected samples randomly from groups stratified by CRP value at the baseline, not simple random samples. Second, the second measurement was performed after freeze/thaw procedure once at the baseline to measure coagulating factors. Third, we could not confirm the effect of evaporation, because other measurements, such as electrolyte: potassium, sodium or chloride, were not done. The samples were stored in tempered tubes to prevent evaporation. Nevertheless, evaporation might have occurred during storage, and CRP values in the second measurement might have increased. We could confirm the linear relationship between the two measurements due to stratified selection. We could not estimate how CRP values change during long-term frozen storage, but the results of the present study might characterize the reliability of the long-term storage data. It is considered reasonable to use CRP values of frozen samples in epidemiological studies to estimate risk ratios, such as odds ratio or hazard ratio. However, we should be careful when determining the cut-off level of CRP values as a risk factor based on values obtained using frozen samples after long-term storage.

In conclusion, the CRP values showed a high correlation between before and after long-term storage. In our data, the values after long-term storage were significantly higher than those before storage, although we could not confirm the effect of evaporation. Other studies to examine differences before and after storage for various periods should be conducted in future.

We appreciated the opportunity to discuss the present study with Dr. J. David Curb.

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
2. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 1999; 20: 954-9.
3. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
4. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
5. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silberschatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the
Stability of CRP on Long-term Storage

Framingham study. Stroke 2001; 32: 2575-9.
6. Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003; 107: 2016-20.
7. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351: 2599-610.
8. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004; 110: 380-5.
9. Danesh J, Wheeler JL, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
10. Wakugawa Y, Kiyohara Y, Tanizaki Y, Kubo M, Ninomiya T, Hata J, et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke 2006; 37: 27-32.
11. Festa A, D'Agostino R, Jr., Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
12. Ridker PM, Buring JE, Cook NR, Rifai N, C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-7.
13. Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004; 97: 101-6.
14. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-3.
15. Ishikawa S, Kayaba K, Gotoh T, Nakamura Y, Kajii E. Metabolic syndrome and C-reactive protein in the general population. Circ J 2007; 71: 26-31.
16. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-9.
17. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.
18. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-10.
19. Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K, et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005; 28: 2497-500.
20. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-25.
21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
22. Macy EM, Haynes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52-8.
23. Aziz N, Fahey JL, Detels R, Butch AW. Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin Diagn Lab Immunol 2003; 10: 652-7.
24. Ishikawa S, Gotoh T, Nago N, Kayaba K. The Jichi Medical School (JMS) Cohort Study: design, baseline data and standardized mortality ratios. J Epidemiol 2002; 12: 408-17.
25. Itoh Y, Ichihara K, Kanno T, Sugawara T, Ohkubo A, Hirabayashi Y, et al. Serum protein standardization project in Japan: evaluation of an IFCC reference material (RPPHS/CRM470) and establishment of reference intervals. J Clin Lab Anal 1997; 11: 39-44.
26. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. Am J Epidemiol 2001; 153: 1183-90.
27. Kayaba K, Ishikawa S, Gotoh T, Nago N, Kajii E, Nakamura Y, et al. Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993-1998. Jpn Circ J 2000; 64: 303-8.
28. Nilsson TK, Boman K, Jansson J-H, Thogersen AM, Berggren M, Broberg A, et al. Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte(TM)) stored at -70 degrees C for 8-11 years. Thromb Res 2005; 116: 249-54.